Portal de Periódicos da CAPES

The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor

2020; Multidisciplinary Digital Publishing Institute; Volume: 12; Issue: 11 Linguagem: Inglês

10.3390/cancers12113254

2072-6694

Andreia Brandão, Paula Paulo, Sofia Maia, Manuela Pinheiro, Ana Peixoto, Marta Cardoso, María P. Silva, Catarina Santos, Rosalind A. Eeles, Zsofia Kote‐Jarai, Kenneth Muir, Johanna Schleutker, Ying Wang, Nora Pashayan, Jyotsna Batra, Henrik Grönberg, David E. Neal, Børge G. Nordestgaard, Catherine M. Tangen, Melissa C. Southey, Alicja Wolk, Demetrius Albanes, Christopher A. Haiman, Ruth C. Travis, Janet L. Stanford, Lorelei A. Mucci, Catharine West, Sune F. Nielsen, Adam S. Kibel, Olivier Cussenot, Sonja I. Berndt, Stella Koutros, Karina D. Sørensen, Cezary Cybulski, Eli Marie Grindedal, Jong Y. Park, Sue A. Ingles, Christiane Maier, Robert J. Hamilton, Barry S. Rosenstein, Ana Vega, Manolis Kogevinas, Fredrik Wiklund, Kathryn L. Penney, Hermann Brenner, Esther M. John, Radka Kaneva, Christopher J. Logothetis, Susan L. Neuhausen, Kim De Ruyck, Azad Razack, Lisa F. Newcomb, Davor Lessel, Nawaid Usmani, Frank Claessens, Manuela Gago‐Dominguez, Paul A. Townsend, Monique J. Roobol, Manuel R. Teixeira,

Ovarian cancer diagnosis and treatment

The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the